Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2019

☐	Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File No. 000-24455

CURAEGIS TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction of incorporation or organization)

16-1509512
(I.R.S. Employer Identification No.)

1999 Mt. Read Blvd. Building 3, Rochester, New York 14615
(Address of principal executive offices and Zip Code)

(585) 254-1100
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☐	Smaller reporting company ☑
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☑

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class		Number of Shares Outstanding at May 15, 2019
Common Stock, $0.01 par value		50, 434,901

Table of Contents

CURAEGIS TECHNOLOGIES, INC.

INDEX

		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of March 31, 201 9 (Unaudited) and December 31, 201 8	3

	Condensed Consolidated Statements of Operations – Three Month Periods Ended March 31, 201 9 and 201 8 (Unaudited)	4

	Condensed Consolidated Statements of Changes in Stockholders’ Defici ency – Three Month Periods Ended March 31, 201 9 and March 31, 2018 (Unaudited)	5

	Condensed Consolidated Statements of Cash Flows – Three Month Periods Ended March 31, 201 9 and 201 8 (Unaudited)	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4.	Controls and Procedures	22

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

SIGNATURE PAGE		24

EXHIBITS

	Exhibit 31.1
	Exhibit 31.2
	Exhibit 32

Table of Contents

CURAEGIS TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2019 (Unaudited)			December 31, 2018
ASSETS
Current Assets:
Cash	$	51,000		$	53,000
Inventory (net)		-			-
Prepaid expenses and other current assets		13,000			25,000
Total current assets		64,000			78,000

Right to use building asset (net)		230,000			-
Property and equipment (net)		55,000			62,000
Software (net)		6,000			10,000
Total non-current assets		291,000			72,000

Total Assets	$	355,000		$	150,000

LIABILITIES AND STOCKHOLDERS' DEFICI ENCY
Current Liabilities:
Liability for inventory held at vendor	$	1,462,000		$	1,462,000
Accounts payable		535,000			323,000
Accrued interest		219,000			166,000
Promissory notes payable		125,000			-
Current right-to-use obligation		109,000			-
Other current liabilities		64,000			40,000
Accrued wages and benefits		61,000			35,000
Total current liabilities		2,575,000			2,026,000

Non-current right-to-use obligation		122,000			-
Senior convertible notes (net)		7,155,000			6,603,000
Total Liabilities		9,852,000			8,629,000

Commitments and other matters		-			-

Stockholders' Defici ency :
Preferred stock, $.01 par value, 100,000,000 shares authorized
Series C, voting, convertible, no dividend, shares issued and outstanding at March 31, 2019 and December 31, 2018: 15,687,500 and 15,687,500, respectively		157,000			157,000
Series C-2, voting, convertible, no dividend, shares issued and outstanding at March 31, 2019 and December 31, 2018: 24,500,000 and 24,500,000, respectively		245,000			245,000
Series C-3, voting, convertible, no dividend, shares issued and outstanding at March 31, 2019 and December 31, 2018: 3,268,000 and 3,268,000, respectively		33,000			33,000
Class A, non-voting, convertible, cumulative dividend $.40 per share per annum, shares issued and outstanding at March 31, 2019 and December 31, 2018: 468,221 and 468,221, respectively		5,000			5,000
Class B, non-voting, convertible, cumulative dividend $.50 per share per annum, shares issued and outstanding at March 31, 2019 and December 31, 2018: 67,500 and 67,500, respectively		1,000			1,000

Common stock, $.01 par value, 400,000,000 shares authorized; shares issued and outstanding at March 31, 2019 and December 31, 2018: 50,400,545 and 50,364,549, respectively		504,000			504,000
Additional paid-in capital		77,855,000			77,725,000
Accumulated deficit		(88,297,000	)		(87,149,000	)
Total Stockholders' Deficiency		(9,497,000	)		(8,479,000	)

Total Liabilities and Stockholders' Deficiency	$	355,000		$	150,000

See notes to condensed consolidated financial statements.

Table of Contents

CURAEGIS TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended March 31, 2019			Three Months Ended March 31, 2018

Revenue and Cost of revenue:
CURA revenue	$	7,000		$	8,000
Cost of revenue		6,000			37,000
Margin (l oss ) on revenue		1,000			(29,000	)

Costs and expenses:
Engineering and development		331,000			405,000
General and administrative		544,000			625,000

Total costs and expenses		875,000			1,030,000

Loss from operations		(874,000	)		(1,059,000	)

Non-operating expense:
Interest expense		(274,000	)		(237,000	)
Other income		-			1,000
		(274,000	)		(236,000	)

Loss before income taxes		(1,148,000	)		(1,295,000	)
Income taxes		-			-
Net loss		(1,148,000	)		(1,295,000	)

Preferred stock dividends		54,000			54,000
Net loss attributable to common stockholders	$	(1,202,000	)	$	(1,349,000	)

Net loss per share attributable to common stockholders
Basic and Diluted	$	(0.02	)	$	(0.03	)
Weighted average number of shares of common stock
Basic and Diluted		50,401,000			49,031,000

See notes to condensed consolidated financial statements.

Table of Contents

CURAEGIS TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIENCY

(Unaudited)

	Class C Preferred Stock				Class C-2 Preferred Stock				Class C-3 Preferred Stock						Class A Preferred Stock				Class B Preferred Stock				Common Stock				Additional Paid		Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares			Amount			Shares		Amount		Shares		Amount		Shares		Amount		in Capital		Deficit			Deficiency

Balance At December 31, 2017		15,937,500	$	159,000		25,000,000	$	250,000		3,388,000		$	34,000			468,221	$	5,000		67,500	$	1,000		48,979,546	$	490,000	$	76,494,000	$	(80,841,000	)	$	(3,408,000	)

Conversion Preferred C-3 to common stock										(80,000	)		(1,000	)										80,000		1,000							-
Stock-based compensation																												2,000					2,000
Issuance of warrants with convertible notes																												208,000					208,000
Beneficial conversion feature on convertible note																												11,000					11,000
Net Loss																														(1,295,000	)		(1,295,000	)

Balance at March 31, 2018		15,937,500	$	159,000		25,000,000	$	250,000		3,308,000		$	33,000			468,221	$	5,000		67,500	$	1,000		49,059,546	$	491,000	$	76,715,000	$	(82,136,000	)	$	(4,482,000	)

Balance At December 31, 2018		15,687,500	$	157,000		24,500,000	$	245,000		3,268,000		$	33,000			468,221	$	5,000		67,500	$	1,000		50,364,549	$	504,000	$	77,725,000	$	(87,149,000	)	$	(8,479,000	)

Issuance of warrants with convertible note																												63,000					63,000
Stock-based compensation																												59,000					59,000
Common Shares issued for interest																								35,996				8,000					8,000
Net Loss																														(1,148,000	)		(1,148,000	)

Balance At March 31, 2019		15,687,500	$	157,000		24,500,000	$	245,000		3,268,000		$	33,000			468,221	$	5,000		67,500	$	1,000		50,400,545	$	504,000	$	77,855,000	$	(88,297,000	)	$	(9,497,000	)

See notes to condensed consolidated financial statements.

Table of Contents

CURAEGIS TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

((Unaudited)

	Three Months Ended March 31, 2019			Three Months Ended March 31, 2018
Cash flows used in operating activities:
Net loss	$	(1,148,000	)	$	(1,295,000	)
Adjustments to reconcile net loss to net cash used in operating activities :
Amortization of debt discount reported as interest		165,000			139,000
Depreciation and amortization		11,000			44,000
Stock-based compensation		59,000			2,000
Interest paid in common stock		9,000			-
Changes in working capital items :
Accounts receivable		-			(6,000	)
Inventory		-			3,000
Prepaid expenses and other current assets		12,000			-
Accounts payable and other current liabilities		315,000			(89,000	)
Net cash used in operating activities		(577,000	)		(1,202,000	)

Cash flows from financing activities:
Proceeds from issuance of senior convertible note (net)		450,000			1,200,000
Proceeds from issuance of unsecured subordinated notes		125,000			-
Net cash provided by financing activities		575,000			1,200,000

Net decrease in cash		(2,000	)		(2,000	)
Cash at beginning of period		53,000			194,000
Cash at end of period	$	51,000		$	192,000

Supplemental Disclosures:
Right to use asset	$	230,000		$	-
Cash used for payment of interest expense	$	47,000		$	80,000
Debt discount related to warrants and beneficial conversion feature	$	63,000		$	219,000
Common stock issued in payment of interest expense	$	8,000		$	-

See notes to condensed consolidated financial statements.

Table of Contents

CURAEGIS TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - THE COMPANY AND BASIS OF PRESENTATION

CurAegis Technologies, Inc. (“CurAegis”, “the Company”) was incorporated as a New York business corporation in September 1996 under the name Torvec, Inc. The Company’s name was changed to CurAegis Technologies, Inc. in 2016 in connection with the establishment of its two business divisions. The CURA division is engaged in the fatigue management business and the Aegis division is engaged in the power and hydraulic business.

The Company has created the CURA System to market products that reduce fatigue risk in the workplace and help individuals manage their sleep and improve alertness. The CURA System consists of the following capabilities:

	●	real-time alertness utilizing the CURA app,
	●	the Group Wellness Index and
	●	the Z-Coach wellness program.

The Aegis hydraulic pump technology has been designed to bring to the marketplace a unique concept in hydraulic pumps and motors that will be:

	●	smaller, lighter and less expensive than conventional pumps and motors,
	●	more efficient,
	●	as reliable,
	●	unique in its ability to scale larger, allowing more powerful pumps and motors.

It is important to note, regarding both the CURA and Aegis products, that the cycle time from the initiation of the sales process to revenue realization can be highly variable especially as a start-up entity. In addition to the activities to be undertaken to implement our plan of operations, we may expand and/or refocus our activities depending upon future circumstances and developments .

Current Cash Outlook and Management Plans

As of March 31, 2019, we have cash on hand of $51,000, negative working capital of $2,511,000, a stockholders’ deficiency of $9,497,000 and an accumulated deficit of $88,297,000. During the three months ended March 31, 2019 we raised $575,000 in proceeds through the issuance of promissory notes, convertible notes and warrants. The proceeds from this private placement has been used to support the ongoing development and marketing of our core technologies and product initiatives.

Management estimates that the 2019 cash needs will be $3 to $3.5 million, based upon the cash used in operations in the fourth quarter of 2018. As of March 31, 2019, the Company’s cash on hand is not sufficient to cover the Company’s future working capital requirements. This raises substantial doubt as to the Company’s ability to continue as a going concern. Management continues to use its best efforts to develop financing opportunities to fund the development and commercialization of the CURA and Aegis products.

Since inception, we have financed our operations by the sale of our securities and debt financings. We need to raise additional funds to meet our working capital needs, to fund expansion of our business, to complete development, testing and marketing of our products, or to make strategic acquisitions or investments. No assurance can be given that necessary funds will be available for us to finance our development on acceptable terms, if at all. Furthermore, such additional financings will involve dilution to our shareholders or may require that we relinquish rights to certain of our technologies or products. In addition, we will experience operational difficulties and delays due to working capital restrictions. If adequate funds are not available from additional sources of financing, we will have to delay or scale back our growth plans.

The Company’s ability to fund its current and future commitments from its available cash depends on a number of factors. These factors include the Company’s ability to (i) launch and generate sales from the CURA division; (ii) generate revenue from the monetization of our hydraulic technologies or; (iii) decrease engineering and development and administrative expenses. If these and other factors are not met, the Company would need to raise funds in order to meet its working capital needs and pursue its growth strategy. Although there can be no such assurances, management believes that sources for these additional funds will be available through either current or future investors.

Table of Contents

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation: The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8-03 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, all adjustments considered necessary for a fair presentation (consisting of normal recurring adjustments) have been included. The results for interim periods are not necessarily indicative of what the results will be for the fiscal year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2018 contained in the Company’s 2018 Annual Report on Form 10-K filed with the SEC.

Consolidation: The condensed consolidated financial statements include the accounts of the Company, our wholly-owned subsidiary Iso-Torque Corporation, and our majority-owned subsidiary, Ice Surface Development, Inc. (56% owned). As of March 31, 2019, each of the subsidiaries is non-operational.

Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. These estimates are subject to a high degree of judgment and potential change. Actual results could differ from those estimates.

Reclassifications: Certain reclassifications may have been made to prior year balances to conform to the current year’s presentation.

Cash: We maintain cash at financial institutions which periodically may exceed federally insured amounts. We have a corporate credit card program through our primary financial institution, JPMorgan Chase Bank, N.A. In connection with this, the Company granted a security interest to the bank in our money market account to act as collateral for the activity within the corporate card program, up to $5,000.

Inventory : Inventory is stated at the lower of cost or net realizable value with cost determined under the average cost method. We have recorded provisions for excess, obsolete or slow-moving inventory based on changes in customer demand and technology developments. Inventory on hand at March 31, 2019 and December 31, 2018 has been fully reserved reflecting a reserve of $1,747,000.

Right to use building asset

The FASB issued ASU No. 2016-02, “Leases,” which requires a lessee to recognize on its balance sheet the assets and liabilities related to long-term leases that were classified as operating leases under previous guidance. An asset is recognized related to the Company's ability to retain the economic benefits and control of the underlying asset. A corresponding liability is recognized related to the Company's obligation to make lease payments over the term of the lease.

The standard became effective for the Company January 1, 2019. The Company utilized the modified retrospective approach to measure the right-to-use operating lease agreement associated with the office building used for our business operations located in Rochester, New York and utilized the practical expedient to not separate lease components from non-lease components. The adoption of this accounting standard did not impact our consolidated loss from operations and had no impact on cash flows.

Software, Property and Equipment: Capitalized software, property and equipment are stated at cost. Estimated useful lives are as follows:

Software (in years)		3
Office equipment (in years)	5	-	7
Leasehold improvements	lesser of useful life or lease term

Depreciation and amortization are computed using the straight-line method. Betterments, renewals and significant repairs that extend the life of the assets are capitalized. Other repairs and maintenance costs are expensed when incurred. When disposed, the cost and accumulated depreciation applicable to assets retired are removed from the accounts and the gain or loss on disposition is recognized in other income (expense). Depreciation and software amortization expense for the three months ended March 31, 2019 and 2018 amounted to $11,000 and $44,000, respectively.

Whenever events or circumstances indicate, our long-lived assets including any intangible assets with finite useful lives are tested for impairment by using the estimated future cash flows directly associated with, and that are expected to arise as a direct result of, the use of the assets. If the carrying amount exceeds the estimated undiscounted cash flows, impairment may be indicated. The carrying amount is compared to the estimated discounted cash flows and if there is an excess such amount is recorded as impairment.

Table of Contents

Fair Value of Financial Instruments: As defined by U.S. GAAP , fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A hierarchy for ranking the quality and reliability of the information is used to determine fair values. Assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3: Unobservable inputs that are not corroborated by market data

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The Financial Accounting Standards Board’s (“FASB”) guidance for the disclosure about fair value of financial instruments requires disclosure of an estimate of the fair value of certain financial instruments. The fair value of financial instruments pursuant to FASB’s guidance for the disclosure about fair value of financial instruments approximated their carrying values at March 31, 2019 and December 31, 2018. The carrying amount of cash, prepaid expenses and other current assets, accounts payable, and accrued expenses approximates their fair value due to their short maturity. The senior convertible notes can be converted into common stock with an underlying value of $5,454,000 as of March 31, 2019 based on the trading price on March 31, 2019.

Revenue Recognition and Deferred Revenue: On January 1, 2018, the Company adopted FASB ASC 606, "Revenue from Contracts with Customers" and all related amendments for all contracts using the modified retrospective method. There was no impact upon the adoption of ASC 606. The Company has determined that the adoption of this standard did not require a cumulative effect adjustment. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. For contracts where performance obligations are satisfied at a point in time, the Company recognizes revenue when the product is shipped to the customer. For contracts where the performance obligation is satisfied over time, as in the Z-Coach sales, the Company recognizes revenue over the subscription period. Revenue from the sale of the Company's products is recognized net of cash discounts, sales returns and allowances. The Company has two sources of revenue: (i) from the sale of CURA System products and (ii) from stand-alone Z-Coach subscriptions.

The Company's net revenue is derived primarily from domestic customers. For the three months ended March 31, 2019 net revenue from products transferred over time amounted to $7,000 and there was no revenue from products transferred at a point in time. One customer accounted for 89% of total Z-Coach subscription sales made during the three months ended March 31, 2019. Our collection terms provide customers standard terms of net 30 days. Future performance obligations are reflected in deferred revenue.

CURA revenue is recognized (a) upon receipt of payment at the point of sale of the CURA app, (b) upon the delivery of myCadian products and (c) upon the company’s satisfaction of all performance obligations as described in customer agreements. The Z-Coach Program provides fatigue training over an annual subscription period of twelve months. The Z-Coach Program allows the user unlimited access during the annual subscription period. Customers are billed at the acceptance of the subscription, and revenue is recognized ratably over the subscription period as our performance obligations are satisfied and when collection is reasonably assured. Our collection terms provide customers standard terms of net 30 days. Future performance obligations are reflected in deferred revenue.

Engineering and Development and Patents: Engineering and development costs and patent expenses are charged to operations as incurred. Engineering and development include personnel-related costs, materials and supplies, depreciation and consulting services. Patent costs for the three months ended March 31, 2019 and 2018 amounted to $10,000 and $31,000, respectively, and are included in general and administrative expenses.

Stock-based Compensation: FASB Accounting Standards Codification (“ASC”) 718-10 requires all share-based payments to be recognized as compensation expense over the service period (generally the vesting period) in the consolidated financial statements based on their fair values on the grant date. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized as a financing activity in accordance with ASC 718-10. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

During 2018, the Company adopted FASB ASU 2018-07, “Equity-Based Payments to Non-Employees,” which requires all share-based payments to non-employees, including grants of stock options, to be recognized in the consolidated financial statements as expense generally over the service period of the consulting arrangement or as performance conditions are expected to be met. FASB ASC 718-20 requires that modifications of the terms or conditions of equity awards be treated as an exchange of the original award for a new award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified. The Company utilized a modified retrospective approach effective as of January 1, 2018 in the adoption of this accounting guidance which resulted in a reduction of $10,000 in stock compensation expense previously recorded costs for options outstanding to non-employees.

Table of Contents

Income Taxes: We account for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax basis of our assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

We account for uncertain tax positions using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax benefits that meet the more-likely-than-not recognition threshold should be measured as the largest amount of tax benefits, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement in the financial statements. It is our policy to recognize interest and penalties related to income tax matters as general and administrative expenses. As of March 31, 2019, and December 31, 2018, there were no accrued interest or penalties related to uncertain tax positions.

Loss per Common Share: FASB’s ASC 260-10 (“Earnings Per Share”) requires the presentation of basic earnings per share, which is based on weighted average common stock outstanding, and dilutive earnings per share, which gives effect to options, warrants and convertible securities in periods when they are dilutive. At March 31, 2019 and 2018, we excluded 96,927,383 and 84,560,427 potential common shares, respectively, relating to convertible preferred stock, convertible notes, options and warrants outstanding from the diluted net loss per common share calculation because their inclusion would be anti-dilutive. In addition, we excluded 625,000 warrants from the diluted net loss per common share calculation at March 31, 2019 and 2018 as the conditions for their vesting are not time-based.

NOTE 3 – INVENTORY AND RELATED VENDOR LIABILITY

The Company had the following inventory held at our manufacturing vendor and on hand as of March 31, 2019 and December 31, 2018:

	March 31, 2019			December 31, 2018
Raw materials	$	1,678,000		$	1,678,000
Finished goods		69,000			69,000
		1,747,000			1,747,000
Less: Reserve for quality		(1,747,000	)		(1,747,000	)
Inventory (net)	$	-		$	-

Liability for inventory held at vendor	$	1,462,000		$	1,462,000

During 2017, the Company initiated a purchase order with a third-party vendor to manufacture and assemble the myCadian watch. In connection with this agreement, the Company agreed to a cancellation charge for products purchased on behalf of the Company in the instance that the purchase order is subsequently modified, delayed or cancelled. The Company has recorded $1,678,000 in inventory and components which were purchased by the vendor on our behalf and a related liability of $1,462,000 for amounts payable in connection with this agreement.

During the 2018, the Company recorded an additional reserve of $1,741,000 in connection with a review of inventory on-hand. This recognizes a reserve for myCadian related components and finished goods on hand at that date. Management will continue to evaluate this reserve in future reporting periods.

NOTE 4 - SENIOR CONVERTIBLE NOTES AND WARRANTS

At March 31, 2019, the Company had $9,610,000 in convertible notes outstanding which have been presented net of unamortized debt discounts of $2,455,000, resulting in a carrying value of $7,155,000. As of December 31, 2018, the Company had $9,160,000 in convertible notes outstanding, presented net of unamortized debt discounts of $2,557,000 resulting in a carrying value of $6,603,000. Scheduled maturities on the Company’s convertible note are: none in the twelve months ending December 31, 2019 and 2020; $2,990,000 in the twelve months ending December 31, 2021; $2,775,500 in the twelve months ending in December 31, 2022; $3,395,000 in the twelve months ending December 31, 2023 and $450,000 thereafter.

Table of Contents

Included in the face value of convertible notes outstanding at March 31, 2019 and December 31, 2018, the Company had outstanding $2,252,500 in convertible notes payable to six of our directors and $1,170,000 in convertible notes payable to an investor that is deemed an affiliate.

	Total			JULY 2018 Convertible Notes			2018 Convertible Notes			2017 6% Convertible Notes			2016 6% Convertible Notes
Face value December 31, 2018	$	9,160,000		$	1,175,000		$	625,000		$	4,370,000		$	2,990,000
Notes issued in current period		450,000			450,000			-			-			-
Face value March 31, 2019	$	9,610,000		$	1,625,000		$	625,000		$	4,370,000		$	2,990,000

Debt discount December 31, 2018	$	(2,557,000	)	$	(360,000	)	$	(231,000	)	$	(456,000	)	$	(1,510,000	)
Debt discount on notes issued in current period		(63,000	)		(63,000	)		-			-			-
Amortization of discount reported as interest		165,000			13,000			11,000			15,000			126,000
Debt discount March 31, 2019	$	(2,455,000	)	$	(410,000	)	$	(220,000	)	$	(441,000	)	$	(1,384,000	)

Senior Convertible Notes (net)	$	7,155,000		$	1,215,000		$	405,000		$	3,929,000		$	1,606,000

JULY 2018 Convertible Notes

In July 2018, the board of directors authorized the issuance of up to $2.5 million in non-interest bearing Senior Convertible Promissory Notes and Warrants (the “JULY 2018 Convertible Notes”) in connection with the July 24, 2018 Securities Purchase Agreement (the “JULY 2018 SPA”). The JULY 2018 Convertible Notes have a five-year maturity.

The conversion rate of the notes was fixed at $0.25 per share as determined at the close of business on July 24, 2018. Investors in this offering were granted warrants to purchase warrants equal to 10% or 25% of the number of shares issuable upon the conversion of the notes based upon the amount of their investment. The warrants have a fixed exercise price of $0.25 and a ten-year term from the date of issuance. The notes were offered in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933 as amended (the "Securities Act") and Rule 506(c) of Regulation D as promulgated by the Securities and Exchange Commission. The offering was available only to “accredited investors” as defined in Rule 501(a) of Regulation D under the Securities Act.

During the three month period ending March 31, 2019, the Company issued $450,000 in new notes and allocated $63,000 of the proceeds to debt discount based on the computed fair value of the warrants and the debt issuance costs on the date of investment. During the three month periods ending March 31, 2019 and March 31, 2018, the Company recorded $13,000 and $0 respectively, in interest expense which reflects the amortization of debt discount.

2018 Convertible Notes

In May 2018, the board of directors authorized the issuance of up to $1 million in non-interest bearing Senior Convertible Promissory Notes and Warrants (the “2018 Convertible Notes”) in connection with the May 8, 2018 Securities Purchase Agreement (the “2018 SPA”). The 2018 Convertible Notes have five-year maturity. On July 19, 2018, the Company’s board approved a resolution to complete this offering. Investments received on the 2018 SPA totaled $625,000 and included the issuance of 460,000 common stock warrants.

The conversion rate of the notes was fixed at $0.25 per share as determined at the close of business on May 8, 2018. Investors in this offering were granted warrants to purchase warrants equal to 10% or 25% of the number of shares issuable upon the conversion of the notes based upon the amount of their investment. The warrants have a fixed exercise price of $0.25 and a ten-year term from the date of issuance. The notes were offered in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933 as amended (the "Securities Act") and Rule 506(c) of Regulation D as promulgated by the Securities and Exchange Commission. The offering was available only to “accredited investors” as defined in Rule 501(a) of Regulation D under the Securities Act.

During the three month periods ending March 31, 2019 and March 31, 2018, the Company recorded $11,000 and $0, respectively in interest expense which reflects the amortization of debt discount.

2017 Convertible Notes

The board of directors authorized the issuance of up to $5 million in 6% Senior Convertible Promissory Notes and Warrants (the “2017 Convertible Notes”) in connection with the May 31, 2017 Securities Purchase Agreement (as amended, the “2017 SPA”). Total investments received on the 2017 SPA totaled $4,420,000 and included the issuance of 2,307,207 common stock warrants. The 2017 Convertible Notes have a five-year maturity and a fixed annual interest rate of 6%. Investors in this offering were granted warrants to purchase warrants equal to 10% or 25% of the number of shares issuable upon the conversion of the notes based upon the amount of their investment.

Table of Contents

The 2017 Convertible Notes were offered in a private placement exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(c) of Regulation D as promulgated by the Securities and Exchange Commission. The offering was available only to “accredited investors” as defined in Rule 501(a) of Regulation D under the Securities Act.

During the three month period ending March 31, 2019 the Company recorded $80,000 in interest expense including $15,000 of amortization of debt discount. During the three month period ended March 31, 2018, the Company recorded $74,000 in interest expense including $21,000 of amortization of debt discount.

2016 Convertible Notes

During 2016, the board of directors authorized, and the Company issued, $3 million in 6% Senior Convertible Promissory Notes and Warrants (the “2016 Convertible Notes”) in connection with the August 25, 2016 Securities Purchase Agreement (the “2016 SPA”). The 2016 Convertible Notes have five-year maturity dates ranging from August 2021 through December 2021 and a fixed annual interest rate of 6%. The initial year of interest expense was paid to the note holders on the first anniversary of each note's issuance and will be paid quarterly thereafter. Principal is due in full on each note's maturity date.

The conversion rate of the notes was fixed at $0.25 per share as determined at the close of business on August 25, 2016. The investors were granted warrants to purchase an aggregate number of shares of common stock equal to 10% of the number of shares issuable upon the conversion of the notes. The warrants have a fixed exercise price of $0.25 and a ten-year term from the date of issuance. The notes were offered in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1934, as amended and Rule 506(c) of Regulation D as promulgated by the Securities and Exchange Commission. The offering was available only to “accredited investors” as defined in Rule 501(a) of Regulation D under the Securities Act of 1933.

During the period ending March 31, 2019, the Company recorded $169,000 in interest expense including amortization of debt discount of $126,000. During the three month period ended March 31, 2018 the Company recorded $163,000 in interest expense including amortization of debt discount of $118,000.

NOTE 5 – UNSECURED SUBORDINATED PROMISSORY NOTES

During the first quarter of 2018, the Company issued $125,000 in unsecured subordinated promissory notes to the Company’s Chief Executive Officer and to another board member. These notes bear an interest rate of 6% per annum and have a maturity date of ninety days from the date of grants.

NOTE 6 – RIGHT-TO-USE BUILDING ASSET

The FASB issued ASU No. 2016-02, “Leases,” which requires a lessee to recognize in its balance sheet the assets and liabilities related to long-term leases that were classified as operating leases under previous guidance. An asset is recognized related to the right to use the underlying asset and a liability is recognized related to the obligation to make lease payments over the term of the lease. The standard became effective for the Company January 1, 2019. The Company utilized the modified retrospective approach to measure the right-to-use operating lease agreement associated with the office building used as our headquarters located in Rochester, New York. The adoption of this accounting standard did not impact our consolidated loss from operations and had no impact on cash flows.

The Company measured the present value of future lease costs at $257,000 which included monthly rental, common area costs, and taxes in measuring the present value of the right-to-use building asset on January 1, 2019. The Company assumed an incremental borrowing rate of 6% as the building lease agreement does not include an implicit rate. The right-to-use asset includes two, one year renewal options that run through May 2021.

Operating lease costs for the first quarter of 2019 were $30,000 with future maturing lease liabilities as follows: 2019: $85,000 for the remaining nine months of 2019; $114,000 in 2020 and $57,000 in 2021. Total future lease payments are $256,000 including imputed interest of $18,000.

NOTE 7 - SOFTWARE

The Company investments in software for the CURA system are amortized over an estimated useful life of 3 years. Amortization expense recognized for the three months ended March 31, 2019 and 2018 was $4,000 and $31,000, respectively. The net value of capitalized software at March 31, 2019 and 2018 was $6,000 and $71,000, respectively. Future amortization expense is expected to be $6,000 in 2019.

Table of Contents

NOTE 8 - PROPERTY AND EQUIPMENT

At March 31, 2019 and December 31, 2018 property and equipment consist of the following:

	March 31, 2019			December 31, 2018
Office equipment	$	249,000		$	249,000
Shop equipment		182,000			182,000
Leasehold improvements		253,000			253,000
		684,000			684,000
Less accumulated depreciation		(629,000	)		(622,000	)
Net property and equipment	$	55,000		$	62,000

Depreciation expense for the three months ending March 31, 2019 and 2018 was $7,000 and $13,000 respectively.

NOTE 9 - BUSINESS SEGMENTS

The Company has two operating business segments. The CURA business operates in the fatigue management industry and the Aegis business is focused in the power and hydraulic industry.

Segment information for the three months ending March 31, 2019 for the Company’s business segments follows:

	CURA		Aegis		Corporate		Total

Revenue	$	7,000	$	-	$	-	$	7,000
Earnings on revenue		1,000		-		-		1,000
Total costs and expenses		339,000		169,000		367,000		875,000
Loss from operations		338,000		169,000		367,000		874,000
Interest and other expense		-		-		274,000		274,000
Net loss	$	338,000	$	169,000	$	641,000	$	1,148,000

Stock based compensation	$	8,000	$	8,000	$	43,000	$	59,000
Depreciation and amortization	$	6,000	$	5,000	$	-	$	11,000
Assets at March 31, 2019	$	9,000	$	50,000	$	296,000	$	355,000

Segment information for the three months ending March 31, 2018 for the Company’s business segments follows:

	CURA			Aegis		Corporate		Total

Revenue	$	8,000		$	-	$	-	$	8,000
Loss on revenue		29,000			-		-		29,000
Total costs and expenses		523,000			131,000		376,000		1,030,000
Loss from operations		552,000			131,000		376,000		1,059,000
Interest and other expense		-			-		236,000		236,000
Net loss	$	552,000		$	131,000	$	612,000	$	1,295,000

Stock based compensation	$	(16,000	)	$	2,000	$	16,000	$	2,000
Depreciation and amortization	$	37,000		$	5,000	$	2,000	$	44,000
Assets at March 31, 2018	$	1,860,000		$	70,000	$	227,000	$	2,157,000

NOTE 10 - PREFERRED and COMMON STOCK

Common Stock

We have authorized 400,000,000 shares of common stock, with a par value of $0.01 per share.

During the three months ending March 31, 2019 we issued 35,996 shares of common stock at $0.25 per share in payment of interest on the Company’s 2016 and 2017 Convertible Notes. During the three months ended March 31, 2018 we issued 80,000 shares of common stock in connection with a conversion notice received from a Series C-3 convertible preferred stockholder.

Table of Contents

Preferred Stock

Our certificate of incorporation permits the Company to issue up to 100,000,000 shares of $.01 par value preferred stock.

Class A Preferred Stock

At March 31, 2019 and December 31, 2018 there were 468,221 outstanding shares of Class A Preferred stock, of which 8,709 shares resulted from the settlement of dividends due to conversion, and those shares no longer accrue dividends. The value of dividends payable upon the conversion of the remaining 459,512 outstanding shares of Class A Preferred stock was $2,576,000 at March 31, 2019 and $2,530,000 at December 31, 2018.

In the event of a liquidation, dissolution and winding up of the Company, and subject to the liquidation rights and privileges of our Class C Preferred stockholders, Class A Preferred stockholders have a liquidation preference with respect to all accumulated and unsettled dividends. The value of the Class A Preferred stockholders’ liquidation preference was $2,576,000 and $2,530,000 at March 31, 2019 and December 31, 2018, respectively. In the event of liquidation, dissolution or winding up of the Company, unpaid accumulated dividends on the Class A Preferred are payable in Class A Preferred at a rate of 1 share of Class A Preferred for each $4.00 of dividends.

Class B Preferred Stock

At March 31, 2019 and December 31, 2018, there were 67,500 outstanding shares of Class B Preferred stock. The value of dividends payable upon the conversion of the outstanding shares of Class B Preferred stock was $462,000 at March 31, 2019 and $454,000 at December 31, 2018.

In the event of liquidation, dissolution and winding up of the Company, and subject to the liquidation rights and privileges of our Class C Preferred stockholders and our Class A Preferred stockholders, Class B Preferred stockholders have a liquidation preference with respect to all accumulated and unsettled dividends. The value of the Class B Preferred stockholders’ liquidation preference was $462,000 and $454,000 at March 31, 2019 and December 31, 2018, respectively. In the event of a liquidation, dissolution or winding up of the Company, unpaid accumulated dividends on the Class B Preferred are payable in Class B Preferred shares at a rate of 1 share of Class B Preferred for each $5.00 of dividends.

Series C Preferred Stock

At March 31, 2019 and December 31, 2018, there were 15,687,500 shares of Series C Preferred stock outstanding. The value of the Series C Preferred stockholders’ liquidation preference was $6,275,000 at March 31, 2019 and at December 31, 2018.

The Series C Preferred shares have a liquidation preference at their stated value per share of $0.40 that is senior to our common stock, and the Company’s Class A Non-Voting Cumulative Convertible Preferred Shares and Class B Non-Voting Cumulative Convertible Preferred Shares. The liquidation preference is payable upon a liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or upon a deemed liquidation of the Company.

The Series C Preferred shares have no right to receive dividends and have no redemption right. The Series C Preferred shares vote with the common stock on an as-converted basis.

Series C- 2 Preferred Stock

At March 31, 2019 and December 31, 2018, there were 24,500,000 shares of Preferred C-2 stock outstanding. The value of the Series C-2 Preferred stockholders’ liquidation preference was $4,900,000 at March 31, 2019 and December 31, 2018.

The Series C-2 Preferred Shares are not entitled to receive preferred dividends and have no redemption right, but are entitled to participate, on an as converted basis; with holders of outstanding shares of common stock in dividends and distributions on liquidation after all preferred shares have received payment in full of any preferred dividends or liquidation preferences. The Series C-2 Preferred Shares vote with the common stock on an as-converted basis. We may not, without approval of the holders of at least two-thirds of the Series C-2 Preferred Shares, (i) create any class or series of stock that is pari passu or senior to the Series C-2 Preferred Shares, (ii) create any class or series of stock that would share in the liquidation preference of the Series C-2 Preferred Shares or that is entitled to dividends payable other than in common stock or Series C-2 Preferred Shares of its own series, (iii) acquire any equity security or pay any dividend, except dividends on a class or series of stock that is junior to the Series C Preferred Shares, payable in such junior stock, (iv) reissue any Series C-2 Preferred Shares, (v) declare or pay any dividend that would impair the payment of the liquidation preference of the Series C-2 Preferred Shares, (vi) authorize or issue any additional Preferred Shares, (vii) change the Certificate of Incorporation to adversely affect the rights of the holders of the Series C-2 Preferred Shares, or (viii) authorize, commit to or consummate any liquidation, dissolution or winding up in which the liquidation preference of the Series C-2 Preferred Shares would not be paid in full.

Series C- 3 Preferred Stock

At March 31, 2019 and December 31, 2018, there were 3,268,000 shares of Preferred C-3 stock outstanding. The Company issued 6,042,000 shares of Series C-3 Voting Convertible Preferred Stock in a private placement transaction during 2016.

Table of Contents

NOTE 1 1 - STOCK OPTIONS

2016 Stock Option Plan The shareholders approved the 2016 Stock Option Plan (the “2016 Plan”) which provides for the grant of up to 3,000,000 common stock options to provide equity incentives to directors, officers, employees and consultants. Two types of options may be granted under the 2016 Plan: non-qualified stock options and incentive stock options. As of March 31, 2019, 1,220,000 options have been granted under the 2016 plan and 1,780,000 options are available for future grant.

2011 Stock Option Plan The shareholders approved the 2011 Stock Option Plan (the “2011 Plan”) which provides for the grant of up to 3,000,000 common stock options to provide equity incentives to directors, officers, employees and consultants. Two types of options may be granted under the 2011 Plan: non-qualified stock options and incentive stock options. As of March 31, 2019, there are 91,500 options are available for future grant under the 2011 Plan.

Under the 2016 and 2011 Stock Option Plans, non-qualified stock options may be granted to our officers, directors, employees and outside consultants. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. In the case of incentive stock options, the exercise price may not be less than such fair market value and in the case of an employee who owns more than 10% of our common stock, the exercise price may not be less than 110% of such market price. Options generally are exercisable for ten years from the date of grant, except that the exercise period for an incentive stock option granted to an employee who owns more than 10% of our stock may not be greater than five years.

During the three months ended March 31, 2019, no stock options were granted. During the three months ended March 31, 2018, 150,000 stock options were granted.

Non-Plan Options On occasion, we have granted non-qualified stock options to certain officers, directors and employees that have been outside of established Company Stock Option Plans. All such option grants have been subsequently authorized by shareholder approval.

Summary For the three months ended March 31, 2019 and 2018, compensation expense related to stock option awards amounted to $59,000 and $2,000, respectively. As of March 31, 2019, there was approximately $238,000 of total unrecognized compensation costs related to outstanding stock options, which are expected to be recognized over a weighted average of 1.1 years.

The weighted average grant date fair value of stock options granted during the three months ended March 31, 2019 and 2018 was zero and $0.33, respectively. The total grant date fair value of stock options vested during the three months ended March 31, 2019 and 2018 was approximately $4,000 and $22,000, respectively.

The fair value of each option granted was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:

	2019		2018
Expected term (years)		-		6.3
Expected forfeiture rate		-		0%
Risk-free rate		-		2.6%
Volatility		-		130%
Dividend yield		-		0.0%

The average risk-free interest rate is based on the U.S. treasury security rate in effect as of the grant date. We determined expected volatility using the historical closing stock price. The expected life was generally determined using the simplified method as we do not believe we have sufficient historical stock option exercise experience on which to base the expected term.

The following summarizes the activity of all of our outstanding stock options for the quarter ended March 31, 2019:

			Weighted		Average
			Average		Remaining		Aggregate
			Exercise		Contractual		Intrinsic
	Shares		Price		Term (years)		Value

Outstanding at January 1, 2019		11,028,500	$	0.49		3.8	$	94,000
Granted		-		-
Exercised		-		-
Canceled or expired		-		-

Outstanding at March 31, 2019		11,028,500	$	0.49		3.5	$	-

Exercisable at March 31, 2019		7,068,500	$	0.58		2.7	$	-

Table of Contents

During the quarter ended March 31, 2019, no options were granted, exercised, cancelled or expired unexercised. During the quarter ended March 31, 2018, no options were exercised, or expired unexercised. During the quarter ended March 31, 2018, the Company cancelled 191,875 options as a result of employee turnover. As of March 31, 2019, there were 2,908,500 stock options outstanding under the 2011 Plan, 2,048,500 of which were vested at that date; leaving 91,500 options available for future grant under the 2011 Plan. Also, as of March 31, 2019, there were 1,220,000 stock options outstanding under the 2016 Plan, 270,000 of which were vested at that date; leaving 1,780,000 options available for future grant under the 2016 Plan.

As of March 31, 2019, the exercise prices of all outstanding stock options ranged from $.22 per share to $1.58 per share.

NOTE 1 2 - WARRANTS

The following summarizes the activity of our outstanding warrants for the three months ended March 31, 2019:

						Weighted
			Weighted			Average
			Average			Remaining			Aggregate
			Exercise			Contractual			Intrinsic
	Shares		Price			Term			Value

Outstanding at January 1, 2019		7,381,707	$	0.46	(A)		7.0	(B)	$	39,000
Granted		330,000		0.25
Exercised		-		-
Canceled or expired		-		-

Outstanding at March 31, 2019		7,711,707	$	0.45	(A)		6.9	(B)	$	31,000

Exercisable at March 31, 2019		7,070,786	$	0.44			7.0	(C)	$	30,000

	(A)	The weighted average exercise price for warrants outstanding as of March 31, 2019 and 2018 excludes 1,750,000 warrants in each period with no determined exercise price.
	(B)	The weighted average remaining contractual term for warrants outstanding as of March 31, 2019 and 2018 excludes 743,500 warrants with no expiration date.
	(C)	The weighted average remaining contractual term for warrants exercisable as of March 31, 2019, and 2018 excludes 118,500 warrants with no expiration date.

NOTE 1 3 - RELATED PARTY TRANSACTIONS

As of March 31, 2019, and December 31, 2018, the Company had outstanding $2,252,500 in principal amounts of senior convertible notes held by six members of our board of directors. These notes represent 7,888,378 of potential shares of common stock at March 31, 2019 and December 31, 2018. Underlying warrants outstanding associated with these notes represent 1,239,285 of potential shares of common stock at March 31, 2019 and December 31, 2018.

During the first quarter of 2019, the Company issued unsecured subordinated promissory notes totaling $125,000 to our Chief Executive Officer and to a board member. These notes have a ninety day term and accrued interest at 6% per annum.

NOTE 1 4 - SUBSEQUENT EVENTS

JULY 2018 Convertible Notes

Subsequent to March 31, 2019, the Company issued $50,000 in new JULY 2018 Convertible Notes and 20,000 warrants.

Unsecured S ubordinated P romissory N otes with Related Party

On each of April 4, 2019 and May 1, 2019, the Company entered into $100,000 unsecured subordinated promissory notes with Richard A. Kaplan the Company’s Chief Executive Officer and a director of the Company. The maturity date of the first note is July 3, 2019, and the maturity date of the second note is July 30, 2019. Interest accrues on the outstanding notes at a rate of 6% per annum.

Common shares Issued in Payment of Interest Expense

Subsequent to March 31, 2019, the Company issued 34,356 shares of common stock representing $8,589 in payment of interest to noteholders.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This report contains certain forward-looking statements that are based on the beliefs of management as well as assumptions made by and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, future demand for our products and services, the successful commercialization of our products, general domestic and global economic conditions, government and environmental regulations, competition and customer strategies, changes in our business strategy or development plans, capital deployment, business disruptions, including those caused by fires, raw material supplies, environmental regulations, and other risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements set forth herein. When used in this report, the words “anticipate”, “believe”, “estimate” or “expect” or words of similar import are intended to identify forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see below and in “Risk Factors” in Item 1A of our 2018 annual report on Form 10-K.

Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim any obligation to update any factors or to publicly announce the results of any revisions to any of the forward-looking statements contained in this quarterly report on Form 10-Q to reflect new information, future events or other developments.

The following discussion and analysis should be read in conjunction with the accompanying condensed consolidated financial statements and notes thereto appearing elsewhere in this Form 10-Q.

Overall Business Strategy

CurAegis Technologies, Inc. (“CurAegis”, “the Company”) was incorporated as a New York business corporation in September 1996 under the name Torvec, Inc. The Company’s name was changed to CurAegis Technologies, Inc. in 2016 in connection with the establishment of its two business divisions. The CURA (Circadian User Risk Assessment) division is engaged in the fatigue management business, and the Aegis division is engaged in the power and hydraulic business.

The Company develops and markets advanced technologies in the areas of safety, wellness and power. The Company is focused on the commercialization of a wellness and safety system (the CURA System) and a uniquely designed hydraulic pump that will be smaller, lighter, less expensive and more efficient than current technology. The Company has not had significant revenue-producing operations. The Company has created the CURA System to market products that reduce fatigue risk in the workplace and help individuals manage their sleep and improve alertness. The CURA System consists of the following capabilities:

	●	real-time alertness monitoring,
	●	the Group Wellness Index, and
	●	the Z-Coach Wellness Program.

The Aegis hydraulic pump technology has been designed to bring to the marketplace a unique concept in hydraulic pumps and motors that will be:

	●	smaller, lighter, and less expensive than conventional pumps and motors,
	●	more efficient,
	●	as reliable, and
	●	unique in its ability to scale larger, allowing more powerful pumps and motors.

It is important to note, regarding both the CURA and Aegis products, that the cycle time from the initiation of the sales process to revenue realization can be highly variable especially for a start-up entity. In addition to the activities to be undertaken by us to implement our plan of operation detailed below, we may expand and/or refocus our marketing activities depending upon future circumstances and developments.

Information regarding the Company and all of our inventions, including regular updates on technological and business developments, can be found on our website www.curaegis.com. The website and its contents are not incorporated by reference into this report.

CURA Division: the CURA System, and Z-Coach e-learning

The Company’s CURA division is developing a proprietary technology and related products designed to (i) measure the decrease in a person’s alertness and (ii) to train individuals on how to improve alertness levels. The CURA System will enable the user and third parties to anticipate and avert undesired or disastrous situations caused by the degradation of alertness. With the information provided from the CURA software analytics, employees can work with Z-Coach, our proprietary sleep training and education solution to correct sleep issues and improve overall wellness.

Table of Contents

During 2018, the Company released an APP that utilizes the CURA algorithm with a Fitbit device with a consumer focus. The APP was further developed throughout 2018 and 2019 to expand the reporting capabilities to other devices and to include an API for corporate users. The Company anticipates updated software for the APP and the API in the second quarter of 2019 in anticipation of mid-year 2019 CURA product sales. We believe this will greatly improve the ease of use and the customer experience. We have also modified our pricing structure which we believe makes it much more attractive to potential customers.

CurAegis has engaged sleep study experts and neurologists to assist with the analysis and validation of our technologies. The Company believes a solutions approach can be created to indicate a “degradation of alertness” and thus give immediate and important information to the user and other parties. Action taken upon a warning of a change in alertness will lead to a better and safer environment. The CURA System is designed to provide real-time alertness monitoring that addresses sleep and fatigue management solutions. This is especially important when an individual’s alertness is essential in properly performing tasks, fulfilling responsibilities and averting disasters. The Company has filed for patent protection for these inventions.

The CURA platform is designed to predict and detect a degradation of alertness in a user and reveal sleep and fatigue problems. The CURA platform will include:

	●	a proprietary tool to guide users and third parties about the alertness of the wearer,
	●	a risk assessment that identifies the degradation of alertness potentially affecting the wearer’s ability to perform tasks,
	●	an assessment for alertness and sleep,
	●	real-time reporting that distills complex data into actionable information on mobile and desktop platforms,
	●	predictive reporting for a user to take action when alertness begins to wane, before fatigue becomes dangerous,
	●	flexible settings to provide employers a customized tool within existing safety definitions and to create protocols for a unique environment, and
	●	pricing that makes it affordable across a broad-based workforce.

The Company has invested in controlled clinical studies at the Sleep and Chronobiology Laboratory at the University of Boulder-Colorado and at the University of Rochester Medical Center. These studies have been used to calibrate our proprietary technologies and algorithms.

The Z-Coach tool is a key component of the CURA platform and was originally created by highly respected fatigue management scientists. We acquired Z-Coach in September 2015. Z-Coach learning topics include: Risks and Costs of Fatigue, Fundamentals of Sleep, Fatigue Mitigation and Countermeasures. Z-Coach participants gain an awareness of the dangers inherent in the lack of sleep and learn to utilize lifestyle tools to make changes to improve their health, mood, productivity and safety.

Aegis Division: Hydraulic Pump

During 2018 the Company initiated discussions with a major hydraulics manufacturer ("the Manufacturer") to evaluate our hydraulics technology. After several productive discussions, the Manufacturer and the Company signed a Memorandum of Understanding ("the MOU") to evaluate an investment in the AEGIS technologies. The Company and the Manufacturer continued discussions through March 18, 2019 when it was determined that the parties had not been able to reach an agreement to proceed. In April 2019, the Company engaged an investment banking firm to provide financial advisory services in connection with a potential sale of the Aegis technologies. Management believes these are valuable assets and will prioritize receiving a fair price for them.

The development of the Aegis hydraulic pump has taken on added significance in light of emissions regulations for off road diesel engines. To help achieve these standards, companies are attempting to run diesel engines, and their hydraulic pumps, at lower rotational speeds. This requires larger displacement hydraulic pumps to be installed to compensate for the decrease in rotational speed. Among other advantages, the Aegis hydraulic pump technology allows a larger displacement pump to fit into the same or smaller footprint than that of existing pumps. This enables manufacturers to keep the current equipment layout without the need for expensive modifications to accommodate larger hydraulic pumps.

The Aegis engineering team has completed a production prototype and is working to align the prototype capability with specific customer applications. The Company has achieved significant milestones in the design and testing of this prototype in recent years. Engineering testing, design and expansion of pump and motor functionality is continuing.

We have invested in software, test equipment and personnel to enhance our development efforts of our hydraulic pump to improve performance while maintaining the advantages we have in weight and scale. We maintain our own testing facility, which eliminates the necessity of third party testing fees and support. Our engineering and design team has progressively made adjustments to the valve and piston technology and these changes have resulted in improvement in the measured efficiency of the pump. We have filed for patent protection for our novel non-rotating group pump concept, and we are also working on additional patents as a result of engineering breakthroughs in our design process. We will continue to design modifications to enhance the overall pump technology.

Table of Contents

Results of Operations for the Three Months ended March 31, 2019 and 2018

Revenue, Cost of Revenue and Margin (l oss ) on Revenue

	For the Three Months Ended March 31,					Variance
	2019		2018			Incr (decr)
Revenue	$	7,000	$	8,000		$	(1,000	)
Cost of revenue		6,000		37,000			(31,000	)
Margin (loss) on revenue	$	1,000	$	(29,000	)	$	30,000

During the three months ended March 31, 2019, the Company recorded $7,000 in revenue from Z-Coach stand-alone sales. During the three months ended March 31, 2018 the Company recorded $4,000 in Z-Coach stand-alone sales and $4,000 in pilot revenue from the CURA System.

The Z-Coach modules have been designed for a range of industry professionals, including aviation, trucking and busing industry and for corporate workers. Z-Coach provides fatigue safety training over a twelve-month subscription period. The user has unlimited access to this tool during the subscription period. Customers are billed at the acceptance of the subscription and revenue is recognized ratably over the subscription period as our performance obligations are satisfied and when collection is reasonably assured.

During the three months ended March 31, 2019, nine Z-Coach subscriptions were sold to two customers resulting in total customer sales of $1,000. As of March 31, 2019, and December 31, 2018, the Company has deferred revenue of $4,000 and $9,000, respectively attributed to Z-Coach subscription revenue that will be recognized ratably as our performance obligations are satisfied.

The Company recorded $6,000 and $37,000 in cost of revenue during the three months ended March 31, 2019 and 2018, respectively. The cost of revenue includes software amortization and hosting fees incurred to provide the Z-Coach product to subscribers. Hosting and related costs were $2,000 and $5,000 in the first quarters of 2019 and 2018, respectively. Software amortization was $4,000 and $31,000 in the first quarters of 2019 and 2018, respectively. Capitalized software of $300,000 was fully amortized during the third quarter of 2018. Software amortization is based upon the straight-line amortization of the capitalized software over an estimated useful life of 36 months. Future amortization cost of capitalized software of $6,300 will be fully amortized by December 31, 2019.

Engineering and Development Costs and Expenses

	For the Three Months Ended March 31,					Variance
	2019		2018			Incr (decr)
Wages and benefits	$	165,000	$	250,000		$	(85,000	)
Professional fee and advisors		129,000		129,000			-
Parts and shop supplies		12,000		22,000			(10,000	)
Computer and software maintenance		7,000		12,000			(5,000	)
Depreciation and amortization		7,000		10,000			(3,000	)
Other costs and expenses		-		3,000			(3,000	)
		320,000		426,000			(106,000	)
Stock based compensation		11,000		(21,000	)		32,000
Total Engineering and Development	$	331,000	$	405,000		$	(74,000	)

Engineering and development expenses for the three months ended March 31, 2019 amounted to $331,000 as compared to $405,000 in the three months ended March 31, 2018. The decrease in wages and benefits, parts and shop supplies is a result of more focused engineering efforts as the Company gets closer to product commercialization. Engineering headcount totaled seven and eight professionals, respectively as of March 31, 2019 and 2018. During the first quarter of 2018, the Company recognized a reduction in stock compensation due to forfeitures as a result in employee turnover during the quarter.

Table of Contents

General and Administrative Costs and Expenses

	For the Three Months Ended March 31,				Variance
	2019		2018		Incr (decr)
Wages and benefits	$	250,000	$	378,000	$	(128,000	)
Professional fees and advisors		87,000		75,000		12,000
Facilities and occupancy		41,000		43,000		(2,000	)
Outbound sales services		62,000		-		62,000
Patents		10,000		31,000		(21,000	)
Insurance		20,000		20,000		-
Conferences and travel		7,000		11,000		(4,000	)
Computer expense		8,000		12,000		(4,000	)
Shareholder support		6,000		18,000		(12,000	)
Depreciation and amortization		-		2,000		(2,000	)
Other costs and expenses		5,000		12,000		(7,000	)
		496,000		602,000		(106,000	)
Stock based compensation		48,000		23,000		25,000
Total General and Administrative	$	544,000	$	625,000	$	(81,000	)

General and administrative expense for the three months ended March 31, 2019 amounted to $544,000 compared to $625,000 in the three months ended March 31, 2018. The decrease of $81,000 of spending in the three months ended March 31, 2019 is attributed to headcount decreases in our sales and operations teams offset by an investment in a third party outbound sales team. Patent costs have decreased since the comparable period in 2018 reflecting the timing of technology development and filings in international and domestic locations. General and administrative headcount was nine and fourteen, respectively, at March 31, 2019 and 2018.

Other Income and Expense

	For the Three Months Ended March 31,				Variance
	2019		2018		Incr (decr)
Interest expense	$	274,000	$	237,000	$	37,000
Other income		-		1,000		(1,000	)
	$	274,000	$	236,000	$	38,000

During the three months ended March 31, 2019, the Company recognized $274,000 in interest expense on the convertible notes which includes $165,000 of amortization on debt discount that is classified as interest expense. Also included in interest expense is $1,000 from 6% unsecured subordinated promissory notes. During the three months ended March 2018, the Company recognized $98,000 in interest expense on the convertible notes and $139,000 of amortization on debt discount offset by $1,000 in income on disposed assets.

The increase in interest expense in the first quarter of 2019 reflects an increase of $334,000 in outstanding principal of 2017 convertible notes that bear interest at 6% per annum resulting in increased interest expense year over year. The increase also reflects an increase in debt discount related to newly issued convertible debt of $501,000 resulting in increased amortization of debt discount reported as interest.

Net Loss for the three months ended March 31, 2019 and 2018

The net loss for the three months ended March 31, 2019 was $1,148,000, compared with a net loss in the three months ended March 31, 2018 of $1,295,000. The net loss attributable to common stockholders for the three months ended March 31, 2019 was $1,202,000 compared to $1,349,000 for the three months ended March 31, 2018.

The weighted average basic and diluted common shares outstanding amounted to 50,401,000 and 49,031,000 for each of the three months ended March 31, 2019 and 2018, respectively. The increase in weighted average basic and diluted shares in the first quarter of 2019 reflects warrants issued on convertible notes and option grants granted since the first quarter of 2018. Basic and diluted loss per common share for each of the three months ended March 31, 2019 and 2018 were $0.02 and $0.03 respectively.

Preferred stock dividends $54,000 were recorded in the three months ended March 31, 2019 and 2018, respectively.

Liquidity and Capital Resources

As of March 31, 2019, the Company had cash on-hand of $51,000, a decrease of $2,000 since the beginning of the year. During the three months ended March 31, 2019 we used $577,000 of cash in operating activities. A net loss of $1,148,000 was adjusted for $244,000 in non-cash expenses for: depreciation, amortization, stock-based compensation and interest paid in shares during the quarter. The Company reported $327,000 in changes in working capital components during the three months ended March 31, 2019. The decrease in cash used in operations in the first quarter of 2019 compared to the first quarter of 2018 was driven by: the decrease in the net loss during the first quarter, increase in amortization of debt discount reported as interest, increase in stock compensation expense combined with the increase in accounts payable and other current liabilities.

Table of Contents

During the first quarter of 2019, the Company issued $450,000 in new convertible debt and $125,000 in unsecured subordinated promissory notes resulting in $575,000 in cash provided by financing activities. During the first quarter of 2018, the Company generated $1,200,000 in cash from financing activities from the issuances of 2017 Convertible Notes.

Current Cash Outlook and Management Plans

As of March 31, 2019, we have cash on hand of $51,000, negative working capital of $2,511,000, a stockholders’ deficit of $9,497,000 and an accumulated deficit of $88,297,000. During the first quarter of 2019 we raised $575,000 in proceeds through the issuance of convertible notes and subordinated promissory notes. The proceeds from these debt issuances have been used to support the ongoing development and marketing of our core technologies and product initiatives.

Management estimates that the 2019 cash needs will be $3 to $3.5 million, based on its current development and product plans. As of March 31, 2019, the Company’s cash on hand is not sufficient to cover the Company’s future working capital requirements. This raises substantial doubt as to the Company’s ability to continue as a going concern. Management continues to use its best efforts to develop financing opportunities to fund the development and commercialization of the CURA and Aegis products.

Since inception, we have financed our operations by the sale of our securities and debt financings. We need to raise additional funds to meet our working capital needs, to fund expansion of our business, to complete development, testing and marketing of our products, or to make strategic acquisitions or investments. No assurance can be given that necessary funds will be available for us to finance our development on acceptable terms, if at all. Furthermore, such additional financings will involve dilution to our shareholders or may require that we relinquish rights to certain of our technologies or products. In addition, we may experience operational difficulties and delays due to working capital restrictions. If adequate funds are not available from additional sources of financing, we will have to delay or scale back our growth plans.

The Company’s ability to fund its current and future commitments from its available cash depends on a number of factors. These factors include the Company’s ability to (i) launch and generate sales from the CURA division; (ii) monetization of our hydraulic technologies or; (iii) decrease engineering and development and administrative expenses. If these and other factors are not met, the Company will need to raise funds in order to meet its working capital needs and pursue its growth strategy. Although there can be no assurances, management believes that sources for these additional funds will be available through either current or future investors.

Critical Accounting Policies

Revenue Recognition

The Company has two sources of revenue: (i) from the sale of CURA products and (ii) from stand-alone Z-Coach subscriptions. Revenue from the sale of CURA system is recognized upon the shipment of myCadian products to a customer and upon the company’s satisfaction of all performance obligations as described in customer agreements. The Z-Coach Program provides fatigue training over an annual subscription period of twelve months. The Z-Coach Program allows the user unlimited access during the annual subscription period. Customers are billed at the acceptance of the subscription, and revenue is recognized ratably over the subscription period as our performance obligations are satisfied and when collection is reasonably assured. Our collection terms provide customers standard terms of net 30 days. Future performance obligations are reflected in deferred revenue.

Income Taxes

We account for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax basis of our assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Stock-Based Compensation

FASB ASC 718-10 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the requisite service period (generally the vesting period) in the consolidated financial statements based on their fair values on the grant date. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized as a financing activity in accordance with FASB ASC 718-10.

Table of Contents

No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

FASB ASC 718-20 requires that modifications of the terms or conditions of equity awards be treated as an exchange of the original award for a new award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

Item 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded, as of March 31, 2019, that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of such period, are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

Changes in Internal Control Over Financial Reporting

There have been no significant changes in our internal control over financial reporting during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There have no significant changes in our internal control over financial reporting during the first quarter of 2019 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The Company issued $50,000 of JULY 2018 Convertible Notes and warrants during the period from April 1, 2019 through the filing of this quarterly report on Form 10-Q.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

The following Exhibits, as applicable, are attached to this Quarterly Report (Form 10-Q). The Exhibit Index is found on the page immediately succeeding the signature page and the Exhibits follow on the pages immediately succeeding the Exhibit Index.

3.1	Certificate of Incorporation, incorporated by reference to Form 10-SB/A, Registration Statement, registering Company’s $.01 par value common stock under section 12(g) of the Securities Exchange Act of 1934.

3.2	Certificate of Amendment to the Certificate of Incorporation dated August 30, 2000, incorporated by reference to Form SB-2 filed October 19, 2000.

3.3	Certificate of Correction dated March 22, 2002, incorporated by reference to Form 10-KSB filed for fiscal year ended December 31, 2002.

3.4	By-laws as amended on January 24, 2002, incorporated by reference to Form 10-KSB filed for fiscal year ended December 31, 2002.

3.5	Certificate of Amendment to the Certificate of Incorporation dated October 21, 2004 setting forth terms and conditions of Class B Preferred, incorporated by reference to Form 10-QSB filed for fiscal quarter ended December 31, 2004.

3.6	Certificate of Amendment to the Certificate of Incorporation dated January 26, 2007 increasing authorized common shares from 40,000,000 to 400,000,000, incorporated by reference to Form 10-K filed for fiscal year ended December 31, 2006.

3.7	Certificate of Amendment to the Certificate of Incorporation dated September 21, 2011 setting forth terms and conditions of Class C Preferred, incorporated by reference to Form 8-K filed with the Securities and Exchange Commission on September 26, 2011.

3.8	Certificate of Amendment to the Certificate of Incorporation of CurAegis, Inc., dated March 28, 2014 setting forth terms and conditions of Series C-2 Preferred, incorporated by reference to Form 8-K filed with the Securities and Exchange Commission on March 28, 2014.

3.9	Certificate of Amendment to the Certificate of Incorporation of CurAegis, Inc., dated February 29, 2016 setting forth terms and conditions of Series C-3 Preferred, incorporated by reference to Exhibit 3.9 of Form 10-K filed for the fiscal year ended December 31, 2015.

3.10	Unsecured Subordinated Promissory Note Agreement dated January 23, 2019 by CurAegis Technologies, Inc. for the benefit of Richard A. Kaplan, incorporated by reference to Exhibit 10.1 to CurAegis Technologies, Inc. Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019.

31.1	Rule 13a-14(a)/15d-14(a) Certifications – CEO

31.2	Rule 13a-14/15d-14 Certifications – CFO

32	Section 1350 Certifications

100	XBRL-related documents
	None.

101	The following materials from CurAegis Technologies, Inc.’s Quarterly Report on Form 10-Q for the three month period ended March 31, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three month periods ended March 31, 2019 and 2018 (ii) Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018, (iii) Condensed Consolidated Statements of Cash Flows for the three month periods ended March 31, 2019 and 2018, and (iv) Notes to Condensed Consolidated Financial Statements*

	* Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CURAEGIS, INC.
Dated: May 15, 2019	By:	/s/ Richard A. Kaplan
		Richard A. Kaplan,
		Chief Executive Officer

Dated: May 15, 2019	By:	/s/ Kathleen A. Browne
		Kathleen A. Browne,
		Chief Financial and Accounting Officer

CurAegis Technologies (CE) (USOTC:CRGS)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more CurAegis Technologies (CE) Charts.

CurAegis Technologies (CE) (USOTC:CRGS)
Historical Stock Chart
From Apr 2023 to Apr 2024

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CRGS CurAegis Technologies Inc (CE)

Latest CRGS Messages

Loading Messages....

Curaegis Technologies, Inc. News

Loading Messages....

Your Recent History